It will conduct basic research on stem cells.
Science Park has added Rohto Advanced Research Hong Kong (RARHK) to its biomedical technology ecosystem, Hong Kong Science and Technology Parks Corporation (HKSTP) announced.
The research firm said that it will conduct basic research on mesenchymal stromal cells and other possible areas for cell therapies, as well as promote its clinical applications in Hong Kong and China.
RARHK is a subsidiary of Rohto Pharmaceutical Co., a Japanese manufacturer of pharmaceutical products, cosmetics and functional foods.
Rohto Pharmaceutical is currently conducting a Phase I/II study of allogenic adipose-derived mesenchymal stromal cells against liver cirrhosis. It has also developed an automated cell culture and storage system which allows large scale manufacturing at low cost.
Do you know more about this story? Contact us anonymously through this link.